When one vector isn’t enough: why dual-vector gene therapy matters
The first FDA-approved dual-AAV gene therapy solves a delivery problem that has limited the field for years. Here is why that matters for rare disease families.
KEY TAKEAWAYS
In April 2026, FDA approved Otarmeni (formerly DB-OTO, from Regeneron), the first gene therapy for genetic hearing loss and the first dual-AAV vector gene therapy.
It treats severe-to-profound hearing loss caused by confirmed variants in both copies of the OTOF gene.
OTOF is too large to fit inside a single AAV. The therapy splits the instruction across two AAV1 vectors and the cell reassembles it.
In the pivotal CHORD trial, 80% of evaluable patients met the primary hearing endpoint.
The approach matters beyond hearing. Many rare disease genes are too big for standard delivery, and dual-vector design expands what is possible.
For many families, finding the gene is not the hard part
For many rare disease families, the problem is not that science cannot find the gene. The problem is that fixing the gene is hard.
In April 2026, FDA approved Otarmeni, a gene therapy for children and adults with severe-to-profound hearing loss caused by confirmed variants in both copies of the OTOF gene. Developed by Regeneron and formerly known as DB-OTO, it is the first FDA-approved gene therapy for genetic hearing loss, and the first FDA-approved dual-AAV vector gene therapy.
That second part matters.
Why does delivery matter so much in gene therapy?
AAV is one of the most important delivery tools in gene therapy. It acts like a tiny vehicle that carries genetic instructions into cells. It also has a major limitation. It can only carry a small package, and many disease genes are too large to fit inside one AAV.
OTOF is one of those genes. It provides the instructions for otoferlin, a protein that helps inner hair cells send sound signals to the auditory nerve. In OTOF-related hearing loss, sound may reach the ear, but the signal does not travel properly to the brain.
The challenge is easy to understand and hard to solve. How do you deliver a gene that does not fit?
How do you deliver a gene that does not fit?
Otarmeni uses a dual-vector approach. Instead of forcing the whole instruction into one AAV, the therapy uses two AAV1 vectors to carry the OTOF material into inner hair cells.
If one envelope is too small, send the message in two envelopes and rebuild it at the destination.
The cell does the reassembly. Each vector carries part of the OTOF instruction, and the inner hair cell puts the pieces back together to make working otoferlin.
Why this approval matters beyond hearing loss
Many rare diseases are caused by genes that are difficult to fit into standard delivery systems. Dual-vector gene therapy expands what may be possible. It suggests that some conditions once considered too technically difficult may become more realistic when the biology, the target tissue, and the safety evidence line up.
There is a second signal worth noting. FDA cleared Otarmeni 61 days after the application was filed, under its national priority voucher program. For families, the speed of a review is not a footnote. Time is a biological variable, and faster paths to decision can mean the difference between treating inside a window and missing it.
What do the early results show?
The early results are meaningful. In the pivotal CHORD trial, Otarmeni was studied in 24 pediatric patients, with 20 evaluable for efficacy, and 80% met the primary hearing endpoint. In the New England Journal of Medicine report on the program, 9 of 12 children met the main hearing endpoint at week 24, 6 could hear soft speech without assistive devices, and 3 reached average normal hearing sensitivity.
Regeneron has said it will provide Otarmeni at no cost in the US.
Who is this for?
This is not a treatment for all hearing loss. Otarmeni is for a specific genetic form. It requires biallelic OTOF variants, preserved outer hair cell function, and no prior cochlear implant in the same ear.
For the families who fit that picture, this is a milestone. A precise diagnosis pointed to a precise therapy. A delivery problem got engineered around. And the gene therapy toolbox grew.
So, what now?
Not every large gene has a treatment today. But more are becoming possible. The lesson for rare disease families is the same one we keep seeing. A confirmed genetic diagnosis is the starting point, and the path from diagnosis to therapy keeps getting more navigable as the tools mature.
Wondering if a variant is actionable?
If your family is facing a rare genetic diagnosis, the first step is understanding whether the variant is treatable. Nome provides free variant analysis to assess whether an individualized therapy is feasible for your specific mutation. nome.bio/contact
About Nome
Nome Therapeutics is the Operating System for Personalized Therapeutics, turning every rare disease patient's genome into an actionable treatment plan and helping execute on it at the lowest cost and highest speed in the industry.
This article is for informational purposes only and does not constitute medical or legal advice.
References
FDA. Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. fda.gov
Regeneron. Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss. regeneron.com
New England Journal of Medicine. DB-OTO gene therapy in children with OTOF-related hearing loss. nejm.org
FDA. Otarmeni prescribing information and approval materials. fda.gov
Functional, sustained recovery of hearing in otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Mol Ther Methods Clin Dev. sciencedirect.com
Research on otoferlin function in inner hair cell synaptic transmission. ncbi.nlm.nih.gov
Research on otoferlin and auditory hair cell exocytosis. ncbi.nlm.nih.gov